/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Bicycle Therapeutics PLC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$7.03 0.0393(3.93%) BCYC at 04 Dec 2025 04:26 PM Biotechnology
Lowest Today 6.78
Highest Today 7.16
Today’s Open 6.93
Prev. Close 6.87
52 Week High 21.50
52 Week Low 6.03
Day’s Range: Low 6.78 High 7.16
52-Week Range: Low 6.03 High 21.50
1 day return -
1 Week return -4.41
1 month return +3.77
3 month return +2.58
6 month return -15.25
1 year return -63.75
3 year return -78.08
5 year return -63.88
10 year return -

Institutional Holdings

Baker Bros Advisors LP 15.71

FCPM III SERVICES BV 4.98

Armistice Capital, LLC 4.04

Westfield Capital Management Company, L.P. 4.01

Siren, L.L.C. 2.90

Point72 Asset Management, L.P. 2.56

T. Rowe Price Associates, Inc. 2.12

Millennium Management LLC 2.08

Long Focus Capital Management, LLC 1.90

Deep Track Capital, LP 1.74

Candriam Luxembourg S.C.A. 1.69

T. Rowe Price Health Sciences 1.56

BNP Paribas Investment Partners SA 1.50

Morgan Stanley - Brokerage Accounts 1.50

Tybourne Capital Management (HK) Ltd 1.43

Harbor Small Cap Growth Instl 1.40

Westfield Capital Mgt Co Sm-Cap Gr Eq 1.40

Bank of America Corp 1.20

Candriam Eqs L Biotech C USD Cap 1.16

Principal Financial Group Inc 1.01

BNP Paribas Health Cr Innovtr Cl Cap 0.82

Principal SmallCap R5 0.78

BNP Paribas US Small Cap ClassicC 0.69

Jefferies Financial Group Inc 0.67

Belfius Equities Cure C Cap 0.53

Woodline Partners LP 0.52

MEDICAL BioHealth EUR Acc 0.50

Principal U.S. Small Cap Equity 0.49

Renaissance Technologies Corp 0.46

Junked Platinum Investment Management Ltd 0.41

UTM IM GBP AXA Framlington Biotech 0.39

Handelsbanken Hälsovård Tema (A1 SEK) 0.29

Westfield Small / Mid Cap Gr Eq CIT C 0.27

iShares Biotechnology ETF 0.23

Principal SmallCap SP 0.19

Undly L&G Future World UK Eq Idx Fd 0.18

Embark Small Cap Equity Retirement 0.16

TD Health Sciences - I 0.16

Silvercrest U.S. Small Cap Growth 0.12

Morgan Stanley Pathway Sm-Md Cp Eq ETF 0.09

Market Status

Strong Buy: 5

Buy: 5

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 476.56 M

PB Ratio 0.8389

PE Ratio 0.0

Enterprise Value -123.71 M

Total Assets 956.87 M

Volume 272906

Company Financials

Annual Revenue FY24:35275000 35.3M, FY23:24830000 24.8M, FY22:14463000 14.5M, FY21:11697000 11.7M, FY20:10390000 10.4M

Annual Profit FY24:35275000 35.3M, FY23:null 0.0M, FY22:14463000 14.5M, FY21:11697000 11.7M, FY20:10390000 10.4M

Annual Net worth FY24:-169031000 -169.0M, FY23:-161543000 -161.5M, FY22:-112717000 -112.7M, FY21:-66819000 -66.8M, FY20:-51010000 -51.0M

Quarterly Revenue Q3/2025:11734000 11.7M, Q2/2025:2920000 2.9M, Q1/2025:9977000 10.0M, Q3/2024:2676000 2.7M, Q2/2024:9371494 9.4M

Quarterly Profit Q3/2025:11734000 11.7M, Q2/2025:-68109000 -68.1M, Q1/2025:-47294000 -47.3M, Q3/2024:481724 0.5M, Q2/2024:7729656 7.7M

Quarterly Net worth Q3/2025:-59100000 -59.1M, Q2/2025:-78952000 -79.0M, Q1/2025:-60754000 -60.8M, Q3/2024:-50802000 -50.8M, Q2/2024:-39856630 -39.9M

Fund house & investment objective

Company Information Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Organisation Biotechnology

Employees 305

Industry Biotechnology

CEO Dr. Kevin Lee M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow